Kenji Morimoto

8PUBLICATIONS
46CO-AUTHORS
ChemotherapyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 07, 2026
A Prospective Observational Study of Anamorelin During Chemoimmunotherapy in Non-Small Cell Lung Cancer With Cachexia (SPIRAL-ANA).

|Jan 20, 2026
Impact of vulnerability on concurrent chemoradiotherapy outcomes in patients with locally advanced non-small cell lung cancer using an integrated clinical trial database.

Kenji Morimoto, Tadaaki Yamada, Naoya Nishioka

|May 19, 2025
Impact of immune-related adverse events on clinical outcomes in patients with advanced non-small cell lung cancer with low PD-L1 expression, focusing on pneumonitis: a multicenter retrospective study in Japan.

Shiho Goda, Tadaaki Yamada, Kenji Morimoto

|Nov 04, 2024
YAP Regulates HER3 Signaling-Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers.

Yuki Katayama, Tadaaki Yamada, Keiko Tanimura

|Aug 01, 2024
Clinical significance of chronic pulmonary aspergillosis in lung cancer patients undergoing anticancer drug therapy.

Kenji Morimoto, Ryosuke Hamashima, Tadaaki Yamada

|Oct 06, 2023
Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells.

Soichi Hirai, Tadaaki Yamada, Yuki Katayama

Pageof 2

Frequent Collaborators

7 joint publications

Tadaaki Yamada

4 joint publications

Koichi Takayama

3 joint publications

Takayuki Takeda

3 joint publications

Masaki Ishida